Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Fentanyl Citrate Pectin-Based Nasal Spray	NCIT_C74028	[A sublingual preparation of a synthetic anilidopiperidine opioid with analgesic activity. After rapid sublingual transmucosal absorption, the active ingredient fentanyl selectively binds to and activates mu-opioid receptors in the central nervous system (CNS), mimicking the effects of endogenous opiates. Due to its quick onset and short duration of action, the administration of fentanyl sublingual spray may relief breakthrough pain.]
Opioid Receptor Agonist	NCIT_C67413	[Any agent that binds to and activates any of the opioid receptor subtypes. Opioid receptor agonists mimic the actions of endogenous opioid peptides.]
Opioid	NCIT_C1506	[A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties. Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)]
Fentanyl Sublingual Spray	NCIT_C74029	[A sublingual preparation of a short-acting, synthetic anilidopiperidine opioid with analgesic activity. After rapid sublingual transmucosal absorption, the active ingredient fentanyl selectively binds to and activates mu-opioid receptors in the central nervous system (CNS), mimicking the effects of endogenous opiates.]
DEPDC1/MPHOSH1 Peptide Vaccine	NCIT_C74023	[A cancer vaccine containing HLA-A*2402-restricted epitopes derived from DEP domain containing 1 (DEPDC1) and M phase phosphoprotein 1 (MPHOSPH1) with potential immunostimulatory and antineoplastic activities. Upon administration, DEPDC1/MPHOSH1 peptide vaccine may elicit a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing DEPDC1 and MPHOSPH1, tumor antigens that are overexpressed in bladder cancer cells.]
Diclofenac Sodium Gel	NCIT_C74024	[A gel formulation of the sodium salt of diclofenac, a nonsteroidal benzeneacetic acid derivative with analgesic, antipyretic and anti-inflammatory activities. Diclofenac binds to and chelates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid (AA) to pro-inflammatory prostaglandins. This agent may also inhibit lipoxygenases, resulting in the inhibition of pro-inflammatory leukotriene synthesis from AA.]
Cyclooxygenase Inhibitor	NCIT_C1323	[Any agent that inhibits prostaglandin G/H synthase (cyclooxygenase or COX), an enzyme that catalyzes the production of prostanoids, including prostaglandins, prostacyclin and thromboxane, from arachidonic acid. Cyclooxygenase inhibitors are a type of non-steroidal anti-inflammatory drug.]
Zoptarelin Doxorubicin	NCIT_C74025	[A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation.]
Doxorubicin Preparation	NCIT_C67502	[A compound drug containing doxorubicin as an active ingredient.]
Eflornithine Hydrochloride Ointment	NCIT_C74026	[An ointment formulation of the hydrochloride salt of an ornithine decarboxylase (ODC) inhibitor with hair-growth inhibitory and potential chemopreventive activities. When administered topically, eflornithine irreversibly inhibits skin ODC activity, thereby inhibiting the synthesis of polyamines; inhibition of polyamine synthesis may result in diminished hair growth and epidermal cell turnover.]
Ornithine Decarboxylase Inhibitor	NCIT_C2088	[Any substance that inhibits ornithine decarboxylase, an enzyme that catalyzes the decarboxylation of ornithine, the rate-limiting, commiting reaction in polyamine synthesis. Polyamines are important for stabilizing DNA structure, for the DNA double strand-break repair pathway, and as antioxidants, and inhibition of ornithine decarboxylase inhibits cell growth.]
Melanoma of the Iris pT4b TNM Finding v7	NCIT_C88682	[Melanoma of the iris with extrascleral extension more than 5 mm in diameter. (from AJCC 7th Ed.)]
Melanoma of the Iris pT4 TNM Finding v7	NCIT_C88680	[Melanoma of the iris with extrascleral extension. (from AJCC 7th Ed.)]
Melanoma of the Uvea Pathologic Primary Tumor TNM Finding v7	NCIT_C88668	[A pathologic finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.]
Melanoma of the Ciliary Body and Choroid pTX TNM Finding v7	NCIT_C88684	[Melanoma of the ciliary body and choroid in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)]
Melanoma of the Ciliary Body and Choroid pT0 TNM Finding v7	NCIT_C88685	[Melanoma of the ciliary body and choroid with no evidence of a primary tumor. (from AJCC 7th Ed.)]
Melanoma of the Iris pT4a TNM Finding v7	NCIT_C88681	[Melanoma of the iris with extrascleral extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)]
Melanoma of the Uvea Pathologic TNM Finding v7	NCIT_C88667	[A pathologic finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification system. Resection of the primary tumor by iridectomy, iridocyclectomy, local resection, or enucleation is needed for complete pathologic staging. Assessment of the extent of the tumor, measured in clock hours of involvement, basal dimensions, tumor thickness, and margins of resection, is necessary. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cM0 TNM Finding v7	NCIT_C88664	[Melanoma of the conjunctiva without evidence of distant metastasis. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cM1 TNM Finding v7	NCIT_C88665	[Melanoma of the conjunctiva with distant metastasis. (from AJCC 7th Ed.)]